Wednesday, July 22, 2015
The pending combination of eResearch Technology (ERT), a leader in patient-centric endpoint data collections, and PHT, a leading electronic diary solutions provider for clinical trials and developer of patient-driven mobile apps, would create the largest company for patient endpoint collection and data analytics in global clinical trials.
Almac, a contract development and manufacturing organization, is collaborating with Bangor University in Wales and Hockley International, a manufacturer and exporter of environmental health and industrial chemical products, on a synthetic biology project to develop novel routes to chemicals.
Global CDMO Almac has expanded its clinical services and technologies capabilities in Asia. The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and manage global trials from the region. Local teams will design, implement and manage drug supply strategies and efficient technology solutions throughout the life of each study.
Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.